Marinomed Biotech AG Stock

Equities

MARI

ATMARINOMED6

Pharmaceuticals

Market Closed - Wiener Boerse 11:37:29 2024-04-26 EDT 5-day change 1st Jan Change
17.5 EUR -2.78% Intraday chart for Marinomed Biotech AG -9.79% -40.07%

Financials

Sales 2024 * 18.19M 19.45M 26.58M Sales 2025 * 23.47M 25.09M 34.3M Capitalization 26.96M 28.83M 39.4M
Net income 2024 * - 0 0 Net income 2025 * 1M 1.07M 1.46M EV / Sales 2024 * 1.48 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1.15 x
P/E ratio 2024 *
56.5 x
P/E ratio 2025 *
13.4 x
Employees 44
Yield 2024 *
-
Yield 2025 *
-
Free-Float 65.1%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.78%
1 week-9.79%
Current month-20.09%
1 month-16.67%
3 months-40.27%
6 months-52.96%
Current year-40.07%
More quotes
1 week
16.50
Extreme 16.5
19.40
1 month
16.50
Extreme 16.5
21.90
Current year
16.50
Extreme 16.5
32.00
1 year
16.50
Extreme 16.5
46.20
3 years
16.50
Extreme 16.5
135.00
5 years
16.50
Extreme 16.5
147.00
10 years
16.50
Extreme 16.5
147.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 05-12-31
Founder 56 05-12-31
Director of Finance/CFO 52 18-07-31
Members of the board TitleAgeSince
Chairman 58 07-12-31
Director/Board Member 68 18-11-20
Director/Board Member - 22-06-14
More insiders
Date Price Change Volume
24-04-26 17.5 -2.78% 4,944
24-04-25 18 -2.44% 1,075
24-04-24 18.45 -2.89% 5,904
24-04-23 19 0.00% 5,247
24-04-22 19 -2.06% 2,448

Delayed Quote Wiener Boerse, April 26, 2024 at 11:37 am

More quotes
Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH is a Austria-based biopharmaceutical company. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases. The company is a spin-off from the University of Veterinary Medicine, Vienna.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
17.5 EUR
Average target price
63 EUR
Spread / Average Target
+260.00%
Consensus

Annual profits - Rate of surprise